

Sponsored by:



BIO BANKING 2019

14 - 15 FEBRUARY | PORTO, PORTUGAL

★ ★ *InterContinental Porto - Palácio das Cardosas* ★ ★

- **Co-located with the Companion Diagnostics & Biomarkers 2019**
- **Limited Offer** to attend this Summit, only 140 seats available
- Follow us on Social Media for the **lastest updates** - **#BIOB19**

DES- CRIP- TION



On 14 & 15 February 2019, Porto will host the **BioTech Pharma Summit: Biobanking 2019**. This year event will bring together the world's leading experts in biorepositories, policy makers, and scientific actors to strengthen knowledge in biobanking as well as explore future advances in the field of biosampling for precision medicine, drug development and health research.

Our distinguished panel includes renowned clinicians, researchers, executives and technical professionals from the biopreservation industry as well as the pioneers for a worldwide human research resource. Moreover, the current era is flooded with new advanced technologies, which culminated with the proliferation of more Biobank institutes globally, acting as a clear indicator of a market growth in the field.

Geographically, the EMEA region is estimated to account for a market share of approximately 44% during the predicted period. The presence of a well-established biobanking system in the Nordic countries, such as Sweden, Norway, Denmark, Finland, and Iceland, is a significant factor that bolsters market growth in this region. This conference will gather biobanking leaders from the north, as well as from across the Atlantic, in order to zoom in the market prospects and understand the dynamics of this fast-paced growing industry.

KEY PRACTICAL LEARNING POINTS



- Biobanking innovative models
- Understand the opportunities and challenges of biosampling
- Learn the latest technological methods and procedures for biopreservation, storage stability and validation, while naming evidence-based best practices
- Explore new sample quality management systems, quality standards and accreditation
- Learn how to maintain a sustainable infrastructure in biobanking
- Debate the social and ethical challenges of biobanking for human research
- Predict the market impact of biobanking in the next decade
- Current market trends and future challenges for biobanking success
- Biobanking development in emerging markets
- Prognosis for the Global Biobanking market in an era of transformative new technologies
- Commercial challenges and opportunities
- Redesigning the biobanking business model
- Clinical Trial Strategies in Biobanking and Drug Development

WHO SHOULD ATTEND



Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists and Medical Doctors of:

- Biobanking Researchers
- Biobanking Faculty Members
- Medical Colleges
- Biobanking Associations and Societies
- Training Institutes
- Cryo storage Companies
- Data Privacy and Management Companies
- Security Officers
- Global Biobanking Companies
- Business Developers
- Biobanking investors
- Lab Managers
- Biopharmaceuticals and Biologics Researchers
- Molecular Technologies
- Intellectual property
- Legislation and Policy Advice
- Drug and Safety Assessment
- Market Strategy
- Biopharmaceuticals
- Chief Scientific Officer
- Clinical Immunology
- Drug Safety Assessment & Risk Management
- Population and Disease Based biobanks
- Bioinnovation
- Intellectual property
- Regulatory Affairs
- Health Economics
- Principal Scientists
- Process Control and Analytical Technologies
- Quality Affairs/ Quality Control
- Regulatory Affairs
- Regulatory Compliance
- Legal Affairs
- R&D
- New Product Development
- Health Economics
- Process Control and Analytical Technologies



The BioTech Pharma Summit:

Biobanking 2019 is the leading event to get through the biobanking's ever-thriving market and convenes key stakeholders from the field, and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing timely challenges and best practices for biobanking product success.

We invite all the participants across the globe to join our scientific gathering in Porto, which aims to reveal the newest data and share innovative ideas from research area of bioengineering and tissue preservation.



SPEAKERS LIST



ALI ISMAIL

Founder & Managing Director at Birka Biostorage

SE



ALISSA M. RESCH

Chief Scientific Officer at Coriell Institute for Medical Research

US



ANNETTE AMON-HASSENZAHL

Clinical Trial Biosample Manager at Merck KGaA

DE



CAOIMHE VALLEY-GILROY

Director, Head of Clinical Trials Biosample Mgmt. at Merck KGaA

DE



JENS K. HABERMANN

President of ESBB

DE



JORDAN MOORE

Field Applications Specialist at Fluidigm

FR



MARYBETH JOSHI

Director, Biobank & Translational Research Core at Duke University Medical Center

US



MERJA PERÄLÄ

Project Manager at Auria Biobank

FI

Learn the current
market trends and
future challenges only
at the Biobanking 2019.



MICHAEL ROEHL

Director of the
Precision Pathology
Biobanking
Center at Memorial
Sloan Kettering
Cancer Center

US



CATHERINE LARUE

CEO at IBBL

LU

Chairman Day 2



JAN-ERIC LITTON

Senior professor
at the Karolinska
Institutet

SE



KARINE SARGSYAN

Chief Operating
Officer at Biobank
Graz

AT



**PASQUALE DE
BLASIO**

Executive Vice
President of
ISENET Biobank

IT



**PEADAR MAC
GABHANN**

Managing Director
at Biostór Ireland

IE



RITA LAWLOR

Biobank and Model
Bank Director at
ARC-NET: Centre
for Applied
Research on Cancer

IT



ROBERT HEWITT

Director
at Biosample
Management Ltd

UK

Chairman Day 1

Over 20 presentations and case studies focusing on the key areas of the biobanking industry including market access strategies, clinical development, commercialization, biostorage and biosampling-analytics at the Biobanking 2019.



ROHIT GUPTA

Executive Director, Stanford Biobank; Executive Director, Clinical Research Services (CTRU)

US



RONNY BABER

Head of the LIFE-Biobank and Preatalytical Laboratory at University Hospital Leipzig

DE



SHONA KERR

Project Manager at MRC HGU, University of Edinburgh

UK



SIGBJØRN GREGUSSON

Executive Manager at BioBank AS

NO



SOFIA SPYROU

Production Manager at NIBSC

UK



SVETLANA GRAMATIUK

President and Medical Director at Ukraine Association of Biobank

UA



VINCENT VON WALCKE-WULFFEN

CEO at BioKryo GmbH

DE



JENNIFER CHEESEMAN-JANES

Administrative Director of Research Duke University

US

SCIENTIFIC AGENDA

Thursday, February 14, 2019

08:00 Registration and Welcome Coffee

08:50 Opening Ceremony by Chairman

BIOBANKING CURRENT STATUS AND FUTURE PROSPECTS

09:00 How clinical biobanks and strategic partnerships can support precision medicine: a Lübeck and ESBB perspective

By *Jens K. Habermann* - President of ESBB

- › Full integration of biobanking into the clinical context allow optimization of precision medicine and translational research
- › Major challenges remain in IT infrastructure, data protection and interconnectivity
- › Optimal utilization begins with sharing of resources, harmonization and standardization
- › National, international and global biobank networks offer new opportunities

09:30 Speed Networking

09:50 Big Data and AI in Science-Driven Biobanking: The Next Frontier

By *Michael Roehrl* - Director of the Precision Pathology Biobanking Center at Memorial Sloan Kettering Cancer Center

- › Pathology as the central academic discipline of science-driven biobanking
- › AI and Natural Language Processing for Big Data annotation
- › Developing next generation diagnostics and companion assays for clinical trials and drug development
- › Proteomics as the “post-genomic revolution”

10:30 Morning Coffee and Networking Break

11:00 Establishment of the VISICORT Foundation Biobank for Eye Disease

By *Peadar Mac Gabhann* - Managing Director at Biostór Ireland

- › Sample Management & Quality Control
- › Eye Disease & the Ageing Population
- › Marketing the Biobank

BIOBANKING ETHICAL AND LEGAL FRAMEWORKS

11:40 Balancing the local and the universal in maintaining ethical access to a genomics biobank

By *Shona Kerr* - Project Manager at MRC Human Genetics Unit, Edinburgh

- › Genomics analyses of quantitative traits and electronic health records in consented population-based studies
- › Governing biobanks: data and sample sharing and managed access
- › Are smaller biobanks still useful (and sustainable) in the era of 500,000 plus cohorts?

12:20 Ensuring personal data protection in the EU under current and future regulatory framework

By *Rita Lawlor* - Biobank and Model Bank Director Research Coordinator at ARC-NET: Centre for Applied Research on Cancer

- › Requirements in data protection law and the upcoming General Data Protection Regulation (GDPR) implementation
- › The impact of EU privacy regulations on biobank data collection
- › Requirements for international collaborations.

13:00 Business Lunch

BIOBANKING STRATEGIC DEVELOPMENT

14:00 Confidently manage sample identity

By **Jordan Moore** - Field Applications Specialist at Fluidigm

- > The Advanta™ Sample ID Genotyping Panel enables laboratories to accurately detect a unique genetic fingerprint from samples at each stage of the sample journey. Developed for use with the Biomark™ HD system and based on microfluidics, the panel contains 96 unique single-nucleotide polymorphism (SNP) variants, and can be customized to specific study goals. By using the high-performing Biomark HD system and Fluidigm microfluidic technology, this workflow will allow you to decrease hands-on time and achieve a significant cost savings as compared to traditional qPCR methods.

14:30 Biobank management model and plan sustainable in developing countries

By **Svetlana Gramatiuk** - President and Medical Director at Ukraine Association of Biobank

- > Biobanking in East Europe
- > The future of the industry in the region

15:00 How research infrastructures can efficiently contribute to translational/personalised medicine?

By **Catherine Larue** - Chief Executive Officer IBBL

- > Which research infrastructures are making an impact?
- > Impact of the integration of research infrastructures on translational and personalised medicine
- > Building bridges between academic research and health industry, for a better European translational and personalised medicine

15:30 Afternoon Tea and Networking Break

16:00 Next-Generation Biobank in Academia

By **Rohit Gupta** - Executive Director, Stanford Biobank; Executive Director, Clinical Research Services (CTRU)

- > Improving big data management solutions through biobank infrastructure
- > Accelerating precision health through rapid access to existing samples and data
- > Designing standardized footprints for real-time 'omics' analysis

16:40 Academic biobanks and industry: overcoming obstacles to efficient collaboration and mutual benefit (presentation on behalf of Trans-Hit Biomarkers Inc)

By **Robert Hewitt** - Director at Biosample Management Ltd

- > An introduction to Trans-Hit Biomarkers
- > Understanding the different cultures and constraints of industry and academia
- > Understanding the needs of academic biobanks and the biospecimen requirements of industry
- > Main bottlenecks for collaboration and solutions to allow cooperation between academic biobanks and industry
- > Additional tailor-made solutions for the individual biobank

17:20 **Panel Discussion: Advancing translational and personalized medicine, fostering collaboration and increasing sustainability through integration of industry and clinical trials into the biobank business model**

Moderated by **Jennifer Cheeseman-Janes** - Administrative Director of Research at Duke University

- > Advancing research depends on the ability to have sustainable resources to support comprehensive clinical and translational studies. This panel is interested in exploring how we as biobankers can work more closely with industry to further precision medicine while increasing biobank sustainability
- > To promote communication about industry and clinical trials, show how they can foster collaboration and increase sustainability, an organized discussion amongst panelists and attendees will investigate the relationship benefits between biobanks and industry

Panelists: **Jens K. Habermann** - at ESBB | **Catherine Larue** - at IBBL | **Robert Hewitt** - at Biosample Management Ltd

18:00 Chairman's Closing Remarks

20:00 Gala Dinner with "Fado Concert"

Friday, February 15, 2019

08:00 Registration and Welcome Coffee

08:20 Opening Address from the Chairman

INNOVATIVE FUTURE OF BIOBANKING

08:30 **GMP Biobanking in 2020**

By **Vincent von Walcke-Wulffen** - CEO at BioKryo GmbH

- > Digitalization
- > Standards
- > Regulatory aspects
- > Data protection

09:10 **The Evolving Role of Biobanks: Developing Metrics to Identify Future Needs**

By **Alissa M. Resch** - Chief Scientific Officer Coriell Institute for Medical Research

- > Monitor demand for samples and sample utilization
- > Note how changes in technology impact QC workflows and pipelines
- > Track issues to ensure continual process improvements
- > Identify future needs of scientific community to ensure biobank remains relevant
- > Develop metrics for strategic decision-making

BIOBANK DATA & QUALITY MANAGEMENT

09:50 **Reproducibility and Reliability of Biobank Data**

By **Jan-Eric Litton** - Senior professor at Karolinska Institutet

10:30 Morning Coffee and Networking Break

11:00 **How quality biobanking starts during the clinical trial**

By **Caioimhe Vallely-Gilroy** - Director, Head of Clinical Trials Biosample Mgmt. at Merck KGaA

Operational challenges and solutions for translating a clinical trial samples into biobank assets

By **Annette Amon-Hassenzahl** - Clinical Trial Biosample Manager at Merck KGaA

11:30 **Hospital Biobank Samples and Data for Real-World Evidence Studies**

By **Merja Perälä** - Project Manager Auria Biobank

- > Longitudinal sample collections with associated EHR information supporting discovery and development towards personalized medicine
- > RWD based feasibility analyses and patient recruitment for clinical trials

BIOPRESERVATION MODELS IN HUMAN BIOSPECIMEN RESEARCH

12:00 **Standardizing terminology and data linking between biorepository, clinical and assay data for downstream analysis**

By **Marybeth Joshi** - Director, Biobank & Translational Research Core at Duke University Medical Center

- > Biobank Data Link Biobank Data Linkage & Outcome
- > Follow-up through linkage to health-related records

12:30 Four essential factors for safe and rational production in an animal biobank

By *Sigbjørn Gregusson* - Managing Director at BioBank AS

- > Traceability
- > Production flow
- > Database-to-Database Information Exchange
- > Pre-analytical work after DNA extraction

13:00 Business Lunch

BEST PRACTICES FOR BIOBANKING: COLLECTION, STORAGE, DISTRIBUTION AND USE OF SPECIMENS

14:00 Biobank Graz: Holistic approach to maintain sample quality

By *Karine Sargsyan* - Chief Operating Officer at Biobank Graz

- > Holistic approach is installed focusing on sample quality and integrity

14:40 Risk management in Biorepositories

By *Ali Ismail* - Founder & Director of Commercial Operations at Birka BioStorage

- > Infrastructure, facilities, equipment and logistics. Expectations and deliveries

15:20 Using the best practices for Biobanking

By *Ronny Baber* - Head of the LIFE-Biobank and Preanalytical Laboratory at University Hospital Leipzig

- > High quality biospecimen for reproducible research
- > From epidemiological to healthcare integrated biobanking
- > Influencing factor for liquid biobanked biospecimen

16:00 Afternoon Tea and Networking Break

RECENT SCIENTIFIC ADVANCES IN STEM CELL RESEARCH

16:30 Stem Cells (iPS)

By *Pasquale De Blasio* - Executive Vice President of ISENET BiobankLeipzig

- > Innovative concepts on Stem Cells Biobanking
- > The importance of Stem Cells Quality Controls
- > Personalized iPS Banking

17:00 Banking of clinical grade human Pluripotent Stem Cells

By *Sofia Spyrou* - Production Manager UK Stem Cell Bank

17:30 Chairman's Closing Remarks

SPEAKERS BIOGRAPHIES



**ANNETTE AMON-
HASSENZAHL, DE**
*Clinical Trial Biosample
Manager at Merck KGaA*



Annette is part of the Clinical Trial biosample management group at Merck KGaA and has responsibilities over early and late phase trials. Annette is involved in strategic alliance partnership management of biosample related vendors and is also the representative for risk base monitoring. Previously, Annette has worked for a clinical research organization as Global Clinical Trial Manager.



CAOIMHE VALLEY-GILROY, DE
*Director, Head of Clinical Trials
Biosample Mgmt at Merck KGaA*



Caoimhe is currently the Global Head of Clinical Trial Biosample Management at Merck KGaA, leading a team of biosample operational experts in the feasibility and execution of biosampling strategy in clinical trials, across all trial phases and indications. Caoimhe has previously worked in a variety of clin ops roles across several companies including Roche, Novartis, Actelion and Fisher.



RITA LAWLOR, IT
*Biobank and Model Bank
Director at ARC-NET: Centre for
Applied Research on Cancer*



Rita is co-founder and director of the ARC-Net biobank and coordinates research activities. She is co-PI for the European funded project on "Integrative Analysis of Gene Functions in Cellular and Animal Models of Pancreatic Cancer" and "Biomarkers of tumour recurrence in pancreatic cancer". She is a former director of ISBER and is past president of ESBB, the European, Middle Eastern and African Society for Biopreservation and Biobanking. She is IAPP (International Association of Privacy Professionals) CIPP/E and CIPM certified for European data protection.



RONNY BABER, DE
*Head of the LIFE-Biobank and
Preanalytical Laboratory at
University Hospital Leipzig*



Since 2010 Ronny is the head of the LIFE-Biobank and the LIFE-Preanalytical laboratory (since 2014) in the Leipzig Research Center for Civilisation Diseases (LIFE). Dr. Baber is a member of the working group in the German Institute for Standardization (DIN) which supports the ISO TC 276 responsible for the ISO norm 20387 on biobanking and BBMRI-ERIC workgroups for the evaluation of CEN standards. Since September 2017 he is designated as Treasurer of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB).



SOFIA SPYROU, UK
*Production Manager
at NIBSC*



Sofia Spyrou has over six years of experience as a production manager. She joined the UK Stem Cell Bank at NIBSC in 2016 and currently manages the day to day banking operations. Her focus is to review, bank and distribute the MRC funded "EUTCD-Grade" human embryonic stem cell lines. This requires following the Human Tissue Authority's directions on meeting the EU Tissue and Cells Directive. Sofia is responsible for overseeing the complete UK Stem Cell Bank banking process which includes due diligence, banking under GMP conditions, validated QC testing and distributing lines to both national and international customers.



KARINE SARGSYAN, AT
*Chief Operating Officer at
Biobank Graz*



Karine worked on and conducted several projects in the health sector with the Ministry of Health and nongovernmental organizations. Since coming to Medical University Graz she worked for the Paediatric Department for a year and has written successful grant proposals collaboratively to fund research in hospital and central laboratory. Currently (since 2012) she is holding also the position of IT manager in Biobank Graz and is/was responsible for acquisition and completion of many effective software programs. Together with her team, since 2007 she developed the Biobank Graz as an interdisciplinary institution.



MICHAEL ROEHL, US
Director of the Precision Pathology Biobanking Center at Memorial Sloan Kettering Cancer Center




Memorial Sloan Kettering Cancer Center

Michael Roehrl M.D., Ph.D., is Director of the Precision Pathology Biobanking Center at Memorial Sloan Kettering Cancer Center, New York, USA. He is dually board-certified in Pathology and Laboratory Medicine. He holds an MD from the Technical University of Munich, a Ph.D. in Biological Chemistry from Harvard University, and trained clinically at Massachusetts General Hospital in Boston.



JORDAN MOORE, FR
Field Applications Specialist at Fluidigm



Jordan Moore is a Senior Field Applications Specialist (FAS) at Fluidigm, helping to ensure that customer projects exceed expectations. Supporting the microfluidics portfolio, he promotes Fluidigm's continued success in Europe and has supported its ever-expanding genomics portfolio. Jordan is now a dual Franco-American national and is based out of Lyon, France.



PASQUALE DE BLASIO, IT
Executive Vice President of ISENET Biobank



Pasquale De Blasio the Executive Vice President of ISENET Biobank. He is also the founder president of ESBB (European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) and Founder of Integrated Systems Engineering srl leader in Tissue Microarray Platforms. Pasquale graduated in Electrical Engineering from Villanova University (PA, USA, 1976), acquired his Master in Engineering Management from Drexel University (PA, USA, 1980) and a Master in Business Administration from Bocconi University (Milano, Italy, 1986).



JENS K. HABERMANN, DE
President of ESBB



Professor Jens K. Habermann, m.d., Ph.D., is director of ICB-L (Interdisciplinary Center for Biobanking-Lübeck) and scientific director of UCCL (University Cancer Center Lübeck) at the University of Lübeck and University Clinic Schleswig-Holstein. He obtained his Ph.D. at the Karolinska Institutet (Stockholm, Sweden) and postdoc training at the NCI, NIH (Bethesda, USA). as specialist in human genetics, he combines clinical routine, biobanking, and cancer research to optimize individualized medicine by targeting tumor heterogeneity and applying liquid biopsies.




PEADAR MAC GABHANN, IE
Managing Director at Biostór Ireland



Peadar joined Schering Plough Corporation and was a key member of staff in the start-up of the first world-wide Biopharma facility in Cork for the production of Interferon in 1983. As Director and board member of Schering Plough Japan, he led the company's research and Asian business development operations. In the past 10 years he co-founded and directed two Life Science start-ups and participated in several international EU FP7 projects. He currently consults with Jacobs Engineering on the design and construction of major Biopharma facilities throughout Europe and runs a certified Tissue Establishment in Ireland.



ROBERT HEWITT, UK
Director at Biosample Management Ltd



Robert Hewitt has a medical degree and PhD and worked in cancer research both as a lecturer in pathology (Nottingham, UK) and a visiting fellow at the NIH (Bethesda, MD). Since 1998 he has established/managed biobanks in London, Saudi Arabia, Singapore and Luxembourg. He was President of ISBER in 2007. He co-founded ESBB in 2010 and served as the sole employee until 2017. After one year of industry experience working for Trans-Hit Biomarkers, he now works independently as a consultant and promotes collaboration between academic biobanks and industry. He runs the 'Drug Targets & Biomarkers' group on LinkedIn.



MERJA PERÄLÄ, FI
Project Manager
at Auria Biobank



Merja Perälä joined Auria Biobank at 2017. Auria is Finland's first biobank established in connection with Turku University Hospital and the University of Turku. Merja works as project manager taking care of biobank sample and data request and granting process for research both in academia and industry. From her previous positions Merja has wide experience in scientific research (PhD in Molecular Biology and author in over 50 peer-reviewed publications), project management, and international research funding within university, research institution and private company settings.



SIGBJØRN GREGUSSON, NO
Executive manager at
BioBank AS



Exam in Veterinary medicine at the University of Veterinary Medicine Hanover (1982). Veterinary Specialist in Public Health medicine (1997->). Technical expert in Microbiology and Food Safety/ Assessor for Scandinavian Accreditation bodies (1986-2017). Clinical practitioner for several years included Public health and Meat control Chief Hygiene officer of the Norwegian Army. Chief Veterinary officer of Municipal food control for more than one decade. Chief Executive Manager of LabNett AS (Ltd) for another decade, a major Norwegian laboratory company . Executive Manager of SpermVital AS (Ltd) in Hamar, Norway.



SHONA KERR, UK
Project Manager at MRC HGU,
University of Edinburgh



Shona has spent the last six years at the University of Edinburgh as project manager of the QTL in Health & Disease programme. Shona sits on the Generation Scotland Access Committee, which has reviewed more than 300 research proposals to ensure that they are scientifically sound, can be supported by the Generation Scotland resource, comply with the aims of biobank and the original consent given by participants. Prior to joining MRC HGU, Shona was the laboratory integration manager for Generation Scotland and directed the implementation of a Laboratory Integration Management System (LIMS) to control sample management from ~24,000 participants across the four Scottish Medical Schools.



ALI ISMAIL, SE
Founder & Managing
Director at Birka Biostorage



Ali Ismail is the founder and the current Managing Director of Birka BioStorage, the global biorepository and biobank, located in Sweden. Ismail started the company in 2010 in Lund, Southern Sweden. Birka's site in Lund is the first certified repository in Scandinavia. The premises are the first cGMP & GDP qualified storage facility in Scandinavia for the banking of biological and pharmaceutical samples. He previously held positions in biotech companies, such as BioInvent International and BioReliance, focusing on process development, GMP manufacturing and safety testing. Since 2014, Ali Ismail started up Resanitec, a clean room control partner company and Insolidex, a CNC workshop company for medical device production.



ROHIT GUPTA, US
Executive Director, Stanford
Biobank; Executive Director,
Clinical Research Services (CTRU)



Rohit began his research at Stanford Medicine in 2003 and now oversees the Stanford Biobank and leads the institute's largest, research focused, ambulatory care group (Spectrum's Clinical & Translational Research Unit). Notably, he's established biorepository and associated big data infrastructure for multiple large-scale biobanks, both locally and globally, while also designing innovative cost-recovery business models for clinical and lab related research services at the university. Rohit is currently leading the strategy, design, and development for the institute-wide biobanking solution, which includes a clinical and 'omics' connected software solution, amongst the many facets of the modernized infrastructure.



CATHERINE LARUE, LU
CEO at IBBL



After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides. She then joined Sanofi Diagnostics Pasteur, at Minneapolis where she was responsible for Assay Development in the immunodiagnostic area. She worked for 7 years as a Director of Business Unit at Bio-Rad. After installing the Biomarkers department in Genfit (Lille, France), she took over the CEO position of the Institute IBBL (Integrated Biobank of Luxembourg) in 2012. She is currently serving as an expert for the European Commission (H2020 and IMI programmes) and for the first Luxembourg Plan Cancer.



VINCENT VON WACKE-WULFFEN, DE
CEO at BioKryo GmbH



Dr. von Walcke-Wulffen studied at the University of Hamburg Business Administration with a minor field of study in chemistry. In 2004 he was a research assistant at the Fraunhofer IBMT in the working group "Cryobank" responsible for legal and administrative aspects of the Fraunhofer Biobank "Eurocryo". Later he became responsible for technical and transport aspects of the biobank. Since 2005 he is the director of the alliance of German Cryobanks e.V. and since 2010 he is founder and managing director of BioKryo GmbH. BioKryo is a GMP-biobank for the storage for cryopreserved samples for later diagnostic and therapeutic use.



JAN-ERIC LITTON, SE
Senior professor
at the Karolinska Institutet



Jan-Eric Litton is a Senior professor at the Karolinska Institutet, Stockholm, Sweden. He was appointed BBMRI-ERIC's first Director General on 22 January 2014 - 1 August 2017, building up one of the largest infrastructure for Health in Europe. He was also heading the development of e-epidemiology by using Internet, cell-phones, digital paper and digital TV for collecting epidemiology data. Before, he was the Executive Director and head of one of BBMRI.se. He was the co-director for the Swedish LifeGene initiative, a prospective cohort based biobank. Since 2012 he is part of the e-science initiative in Sweden. Since 2018 he is also the chair for the medical start up company VizzDAT AB.



ALISSA M. RESCH, US
Chief Scientific Officer at
Coriell Institute for Medical
Research



As head of scientific operations at the Coriell Institute for Medical Research, Dr. Resch oversees the scientific functions of the institute, including management of the contracts & grants portfolio and oversight of the research and project management teams. Prior to her role as Chief Scientific Officer, Alissa served as Director of Biobanking Operations. Before joining Coriell, Alissa was an Assistant Professor of Genetics and Developmental Biology at the University of Connecticut, where she conducted research in the field of RNA and stem cell biology. Alissa earned her PhD from the University of California, Los Angeles and completed a postdoctoral fellowship in Genomics and Bioinformatics at the National Center for Biotechnology Information (NCBI) at the National Institutes of Health.



MARYBETH JOSHI, US
Director, Biobank & Translational
Research Core at Duke
University Medical Center



Marybeth has been instrumental in the development, implementation, and management of biospecimen and clinical data repositories and associated experimental data with the ability to transform working hypotheses into fully executable projects with defined benchmarks, goals, and measurable objectives. In 2010, she was asked to partner with Director of the Duke BioBank (now BioDuke) to move forward the institution's goal of developing and implementing Duke University's first enterprise-wide biorepository. Currently, Marybeth serves as the School of Medicine's Standard Terminology Manager for the enterprise-wide biobanking effort.



SVETLANA GRAMATIUK, UA
President and Medical Director
at Ukraine Association of
Biobank



Svetlana Gramatiuk serves as President of UAB (Ukraine Associated of Biobank) that she co-founded in 2017. She was also the Medical Director Research Biobank ASK-Health (2015-2016) and the Ukraine Editor of the journal Advanced research biobank and pathophysiology from 2017. Svetlana has also Master of Science Biobanking in Medical University Graz and has an in-depth knowledge of oncology biomarker research in the position holding a from Head Department Medical and Research Laboratory in the Hrigoriev Radiology and Oncology Institute and having completed a Post-Doctoral Fellowship at the Kharkiv National Medical University (Department Pathophysiology from Kharkiv - Ukraine).



JENNIFER CHEESE-MAN-JANES, US
Administrative Director of
Research Duke University



Jennifer has over 14 years of experience in the scientific and technical management of clinical, basic science, and translational research. Extensive knowledge of proposal development, financial planning, project management, regulatory and institutional compliance, and improvement of organizational efficiency within the academic setting at both divisional and departmental levels. She serves as the biobanking lead of two Department of Defense biobanking consortiums in collaboration with Duke University, the Department of Surgery, and the Surgical Critical Care Initiative (SC2i), supporting precision medicine in wounded warriors and the Vascular Composite Allograft Collaborative Initiative (VCAci), supporting translational research in hand transplantation.

Sponsors



Partners



VENUE

InterContinental Porto - Palácio das Cardosas



Location

The hotel stands prominently at the end of Porto's main avenue, Avenida dos Aliados, and is hence in the most central part of the city. The São Bento train station is just 100 metres away and the iconic Clérigos Tower is a three-minute walk.



Service & facilities

Facilities include a delightfully fragranced wellness centre where a range of massages are offered (the candle wax massage is highly recommended), as well as facial treatments and waxing services. The centre also includes a decent-sized 24-hour gym and sauna, but no pool or steam room.



Food & drink

The hotel includes the classy Bar das Cardosas, which offers live music most nights of the week, and the Astória Restaurant, where we sampled a seasonal degustation with sommelier wine pairing.

The biobanking market is expected to reach USD 2.69 Billion by 2022 from USD 1.72 Billion in 2016 at a CAGR of 7.8%. Learn the current market trends and future challenges only at the **Biobanking 2019**

EPMGroup

